Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Arcutis Biotherapeutics (ARQT) Equity Ratio: 2020-2025

Historic Equity Ratio for Arcutis Biotherapeutics (ARQT) over the last 6 years, with Sep 2025 value amounting to 0.43.

  • Arcutis Biotherapeutics' Equity Ratio rose 18.97% to 0.43 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.43, marking a year-over-year increase of 18.97%. This contributed to the annual value of 0.45 for FY2024, which is 73.85% up from last year.
  • As of Q3 2025, Arcutis Biotherapeutics' Equity Ratio stood at 0.43, which was up 8.06% from 0.39 recorded in Q2 2025.
  • In the past 5 years, Arcutis Biotherapeutics' Equity Ratio ranged from a high of 0.96 in Q2 2021 and a low of 0.16 during Q3 2023.
  • Over the past 3 years, Arcutis Biotherapeutics' median Equity Ratio value was 0.39 (recorded in 2025), while the average stood at 0.36.
  • In the last 5 years, Arcutis Biotherapeutics' Equity Ratio plummeted by 70.03% in 2023 and then skyrocketed by 124.60% in 2024.
  • Quarterly analysis of 5 years shows Arcutis Biotherapeutics' Equity Ratio stood at 0.73 in 2021, then slumped by 36.04% to 0.47 in 2022, then slumped by 44.32% to 0.26 in 2023, then spiked by 73.85% to 0.45 in 2024, then rose by 18.97% to 0.43 in 2025.
  • Its Equity Ratio stands at 0.43 for Q3 2025, versus 0.39 for Q2 2025 and 0.41 for Q1 2025.